Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis

Launched by DAEWOONG PHARMACEUTICAL CO. LTD. · Apr 21, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of Fexuclue tablets, a medication for people with gastritis, which is inflammation of the stomach lining. The goal is to see how well these tablets can help improve symptoms related to gastritis, based on feedback from patients before and after they take the medication. The trial is not yet recruiting participants but will include adults aged 19 to 75 who have at least one symptom of gastritis that needs treatment and are able to give informed consent to participate.

To be eligible, participants must be scheduled to receive Fexuclue and be able to understand the study details. However, those who cannot take Fexuclue for specific medical reasons or are considered unsuitable by the doctor cannot participate. If you join this study, you can expect to track your symptoms and see how they change with the treatment. This study aims to provide valuable information about how effective Fexuclue is for improving the quality of life for those suffering from gastritis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult subjects between the ages of 19 and 75 years at the time of obtaining written informed consent.
• • Subjects who are scheduled to receive Fexuclu tablets (fexuprazan) in accordance with the approved indication.
• • Subjects who present with at least one subjective symptom requiring medical treatment
• • Subjects who are capable of understanding the information provided, have voluntarily decided to participate in this observational study, and have provided written informed consent for the use of their personal data.
• Exclusion Criteria:
• • Individuals who fall under any contraindications for the administration of Fexuclu tablets (fexuprazan) as specified in the approved labeling.
• • Individuals who are deemed by the investigator (attending physician) to be inappropriate for participation in this observational study for any reason not otherwise specified.